How can you achieve

IMPACT?

The BD MAX™ System can help with:

- **Workflow efficiency** for timely patient management[1-3]
- Diagnostic **speed and accuracy** to aid in fast, appropriate treatment[1,2,4,5]
- Platform **versatility** to meet emerging testing needs.[6]

Expand your lab's molecular testing potential. It's possible with the BD MAX System.

BD

How can you achieve

MAX efficiency?

Optimize patient care with speed and accuracy



Less than 1.5 minutes hands-on time per specimen[6]

15 minutes hands-on time per run[2,6]

Approximately 3 hours* sample-to-answer per test[6,7]

*Based on processing 24 samples.

MAX performance?

Diagnostics that improve testing accuracy and patient management

MAX versatility?

With clinically relevant and differentiated menu offerings

UP TO **24** SAMPLES PER RUN



MIX AND MATCH **DIFFERENT ASSAYS** ON THE SAME RUN

A broad, expanding suite of molecular solutions

Enteric Solutions

- Enteric Bacterial Panel
- Extended Enteric Bacterial Panel
- Enteric Parasite Panel
- Enteric Viral Panel†

Women's Health and STIs

- CT/GC/TV
- GBS
- Vaginal Panel

Healthcare-Associated Infections

- Cdiff
- Check-Points CPO†
- MRSA *XT*
- StaphSR

TB Solutions

- MDR-TB

Open-System Reagents

- DNA or TNA Extraction
- DNA or TNA Amplification

†Product CE marked, not for sale in the U.S.

The BD MAX™ System is cleared, market-authorized, or approved by the FDA only when used with BD MAX™ IVD assays that have been cleared, market-authorized, or approved by the FDA. IVD assays, research use only (RUO) assays, and user-defined protocols (UDP) cannot be combined in the same rack.

Ask your BD representative how the BD MAX System can help you achieve maximum impact.

Visit BDMAXDIFFERENCE.COM

REFERENCES:

1. Centers for Disease Control and Prevention. Recommendations for the laboratory-based detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae*—2014. *MMWR Recomm Rep*. 2014;63(RR-02):1-19. 2. Hirvonen JJ et al. Comparison of BD Max Cdiff and GenomEra *C. difficile* molecular assays for detection of toxigenic *Clostridium difficile* from stools in conventional sample containers and in FecalSwabs. *EJCMID.* 2015;34(5):1005-1009. 3. Mortensen JE et al. Comparison of time-motion analysis of conventional stool culture and the BD MAX Enteric Bacterial Panel (EBP). *BMC Clin Pathol.* 2015;15:9. 4. Le Guern R et al. Evaluation of a new molecular test, the BD Max Cdiff, for detection of toxigenic *Clostridium difficile* in fecal samples. *J Clin Microbiol.* 2012;50(9):3089-3090. 5. Bauman M. Transitioning from culture to molecular: implementation and integration of BD Max Enteric Bacterial Panel at Cincinnati Children's Hospital. ADVANCE Healthcare website. http://laboratory-manager.advanceweb.com/SharedResources/Downloads/2015/051815/bd_advertorial.pdf. Updated June 2015. Accessed June 1, 2016. 6. Felder RA et al. Process evaluation of an open architecture real-time molecular laboratory platform. *J Lab Autom.* 2014;19(5):468-473. 7. BD MAX™ Enteric Bacterial Panel [package insert]. Becton, Dickinson and Company: Franklin Lakes, NJ; 2016.

BD Life Sciences
30 Tuas Ave 2
Singapore 639461

bd.com

1-223834-US BD-8944